Recently Issued Guidance Documents
Should you find a Web link (URL) embedded within guidance documents that does not work or other documents posted on the FDA Web site, please try searching for the document using the document title. If you need further assistance, please go to Contact FDA.
-
Providing Submissions in Electronic Format—Postmarketing Safety Reports; Guidance for Industry
CDER/CBER, April 2022 -
Drug Products, Including Biological Products, that Contain Nanomaterials; Guidance for Industry
CDER/CBER, April 2022 -
Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet; Draft Guidance for Industry
CDER/CBER, April 2022 -
Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers; Draft Guidance for Industry
CDER/CBER/CDRH/CVM/CFSAN/CTP/ORA, April 2022 -
E8(R1) General Considerations for Clinical Sutdies; Guidance for Industry
CDER/CBER, April 2022 -
Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs; Guidance for Industry
CDER/CBER, April 2022 -
Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, April 2022 -
Emergency Use Authorization for Vaccines to Prevent COVID-19; Guidance for Industry
(Updated March 31, 2022) CBER, March 2022 -
An Acceptable Circular of Information for the Use of Human Blood and Blood Components; Guidance for Industry
(Updated March 22, 2022) CBER, March 2022 -
Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4; Guidance for Industry
CDER/CBER/CDRH/OCP, March 2022 -
Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Draft Guidance for Industry
CBER, March 2022 -
Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry
CBER, March 2022 -
Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry
CDER/CBER, March 2022 -
Inclusion of Older Adults in Cancer Clinical Trials
CDER/CBER/OCE, March 2022 -
Expansion Cohorts: Use in First-in-Human Clinical Trials; Guidance for Industry
CDER/CBER, March 2022 -
Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics; Guidance for Industry
CDER/CBER/OCE, March 2022 -
Drug Product Tracing: The Effect of Section 585 of the FD&C Act - Questions and Answers; Guidance for Industry
CDER/CBER/ORA, February 2022 -
Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic; Guidance for Industry
CDER/CBER/OCE, February 2022 -
Patient-Focused Drug Development: Methods to Identify What Is Important to Patients; Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders
CDER/CBER, February 2022 -
Population Pharmacokinetics; Guidance for Industry
CDER/CBER, February 2022 -
Clinical Pharmacology Considerations for Antibody-Drug Conjugates; Draft Guidance for Industry
CDER/CBER, February 2022 -
Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format; Draft Guidance for Industry
CDER/CBER, February 2022